Clinical Trial Update: Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures [Phase 3]

View source ↗

Summary

A Phase 3 safety and efficacy study of cenobamate (Xcopri) in pediatric patients aged 2-17 with partial-onset seizures is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Partial Epilepsy

Drugs mentioned

• Xcopri (cenobamate)

Snippet

Sponsor: SK Life Science, Inc. | Conditions: Partial Epilepsy | Phase 3 | Status: ACTIVE_NOT_RECRUITING